Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Jul 1.
doi: 10.1007/s13318-025-00955-2. Online ahead of print.

Association of CYP3A5, ABCB1, and CYP2C8 Polymorphisms with Renal Function in Kidney Transplant Recipients Receiving Tacrolimus

Zühal Kaltuş  1 , Nuşin Harmancı  2 , Garip Şahin  3 , Engin Yıldırım  2
Affiliations

Association of CYP3A5, ABCB1, and CYP2C8 Polymorphisms with Renal Function in Kidney Transplant Recipients Receiving Tacrolimus

Zühal Kaltuş et al. Eur J Drug Metab Pharmacokinet. .

Abstract

Background/objectives: Tacrolimus (TAC, FK-506) is a calcineurin inhibitor commonly used to prevent organ rejection in transplant patients. It has a narrow therapeutic index and nephrotoxic effects, characterized by interindividual dose variability. TAC is metabolized by the CYP450 (CYP3A5, CYP3A4) enzyme system and transported by P-glycoprotein (ABCB1). Additionally, the CYP2C8 enzyme has been suggested to play a protective role against both graft rejection and drug-induced toxicity. Genetic polymorphisms in these pathways may influence the risk of tacrolimus-related nephrotoxicity. This retrospective cohort study was conducted to evaluate the association between CYP3A5, ABCB1, and CYP2C8 gene polymorphisms and renal function in kidney transplant recipients METHODS: This study investigated the impact of CYP3A5, ABCB1 and CYP2C8 polymorphisms on blood TAC level and kidney function in renal transplant patients. Genotyping was conducted to determine allele frequencies for CYP3A5 (6986A>G), ABCB1 (13435C>T), and CYP2C8 (A1196G) polymorphisms. Renal function was assessed by measuring serum creatinine, estimated glomerular filtration rate (eGFR), and protein/creatinine ratios at 3, 6, and 12 months post-transplantation.

Result: At 12 months post-transplant, the median serum creatinine level was significantly higher in patients with CYP2C8 (*1/*3 and *3/*3) genotypes compared to those with the CYP2C8*1/*1 genotype (p = 0.021). Additionally, the increase in creatinine from the 3rd to the 12th month was significantly greater in the CYP2C8 (*1/*3 and *3/*3) group (p = 0.036). No significant differences were observed in TAC dosage, blood concentration, or renal function between ABCB1 genotype groups. Although daily TAC doses differed significantly between CYP3A5 genotypes, renal function did not significantly vary.

Conclusion: In light of these data, CYP2C8 gene polymorphism has been associated with an increase in serum creatinine, one of the key markers of renal function. ABCB1 gene polymorphism showed no association while CYP3A5 gene polymorphism influenced TAC dose; however, further studies with larger cohorts are required to clarify these associations.

PubMed Disclaimer

Conflict of interest statement

Declarations. Funding: This study was supported by Eskisehir Osmangazi University Scientific Research Projects Commission (19.0.9.2019/48- ESOGU BAP: Project no. 2019/2742). Conflicts of Interest: The authors confirm that there are no conflict of interest to declare. Ethics approval: The study was conducted after receiving approval from The Eskisehir Osmangazi University Non-interventional Clinical Research Ethics Committee granted approval for this study (permit no. 48/19.09.2019). Consent to Participate: Informed consent was obtained from all individual participants included in the study. Availability of Data and Material: The datasets generated during and/or analysed during the current study are available from the corresponding author on reasonable request. Consent for Publication: Not applicable. Code Availability: Not applicable. Author’s Contributions: Z.K., E.Y. and G.Ş. defined the research question and developed the experimental protocols. Z.K. and N.H. performed all the experiments and analyzed the data. Z.K. drafted the manuscript. Z.K., E.Y. and G.Ş. critically revised the manuscript.

Similar articles

See all similar articles

References

    1. Op den Buijsch RA, Christiaans MH, Stolk LM, de Vries JE, Cheung CY, Undre NA, et al. Tacrolimus pharmacokinetics and pharmacogenetics: influence of adenosine triphosphate-binding cassette B1 (ABCB1) and cytochrome (CYP) 3A polymorphisms. Fundam Clin Pharmacol. 2007;21(4):427–35. - PubMed - DOI
    1. Hawwa AF, McKiernan PJ, Shields M, Millership JS, Collier PS, McElnay JC. Influence of ABCB1 polymorphisms and haplotypes on tacrolimus nephrotoxicity and dosage requirements in children with liver transplant. Br J Clin Pharmacol. 2009;68(3):413–21. - PubMed - PMC - DOI
    1. Voora S, Adey DB. Management of KIDNEY transplant recipients by general nephrologists: core curriculum 2019. Am J Kidney Dis. 2019;73(6):866–79. - PubMed - DOI
    1. Miedziaszczyk M, Bajon A, Jakielska E, Primke M, Sikora J, Skowronska D, et al. Controversial interactions of tacrolimus with dietary supplements, herbs and food. Pharmaceutics. 2022;14(10):2154. - PubMed - PMC - DOI
    1. Bekersky I, Dressler D, Mekki QA. Effect of low- and high-fat meals on tacrolimus absorption following 5 mg single oral doses to healthy human subjects. J Clin Pharmacol. 2001;41(2):176–82. - PubMed - DOI

LinkOut - more resources